PIP4K2A (D83C1) Rabbit mAb #5527
- WB
Supporting Data
REACTIVITY | H M R Mk B Pg |
SENSITIVITY | Endogenous |
MW (kDa) | 50 |
Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
- Mk-Monkey
- B-Bovine
- Pg-Pig
Product Information
Product Usage Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
The antigen sequence used to produce this antibody shares 100% sequence homology with the species listed here, but reactivity has not been tested or confirmed to work by CST. Use of this product with these species is not covered under our Product Performance Guarantee.
Species predicted to react based on 100% sequence homology:
Source / Purification
Background
The levels of PI 5-P change significantly in response to physiological and pathological stimuli (5-12), as well as cell transformation with nucleophosmin anaplastic lymphoma tyrosine kinase (13). In contrast, hypoosmotic shock and histamine decrease cellular levels of PI 5-P (14,15). PIP4K2A has been hypothesized to play a role in suppressing mitogen-dependent increases in PI 5-P in response to DNA damage and cellular stress (16-18). PIP4K2A regulates the levels of PI 5-P in the nucleus by converting the PI 5-P to PI 4,5-P2, thus preventing PI 5-P from interacting with and regulating the ability of ING2 to activate p53 and p53-dependent apoptotic pathways (19). PIP4K2A has been shown to form a heterodimer with PIP4K2B resulting in its recruitment to the nucleus. Interestingly, PIP4K2A is 2000-fold more active than PIP4K2B in this context, suggesting that the two lipid kinases act in tandem, with PIP4K2B acting as the targeting subunit and PIP4K2A the catalytic component (18). PIP4Ks may also play a role in lipid vesicle formation and/or Golgi homeostasis (20).
- Divecha, N. et al. (1995) Biochem J 309 ( Pt 3), 715-9.
- Boronenkov, I.V. and Anderson, R.A. (1995) J Biol Chem 270, 2881-4.
- Rameh, L.E. et al. (1997) Nature 390, 192-6.
- Stopkova, P. et al. (2003) Am J Med Genet B Neuropsychiatr Genet 123B, 50-8.
- Schwab, S.G. et al. (2006) Mol Psychiatry 11, 837-46.
- Bakker, S.C. et al. (2007) Genes Brain Behav 6, 113-9.
- Fedorenko, O. et al. (2008) Psychopharmacology (Berl) 199, 47-54.
- Salazar, G. et al. (2009) J Biol Chem 284, 1790-802.
- Morris, J.B. et al. (2000) FEBS Lett 475, 57-60.
- Sbrissa, D. et al. (2004) Endocrinology 145, 4853-65.
- Guittard, G. et al. (2009) J Immunol 182, 3974-8.
- Sarkes, D. and Rameh, L.E. (2010) Biochem J 428, 375-84.
- Coronas, S. et al. (2008) Biochem Biophys Res Commun 372, 351-5.
- Sbrissa, D. et al. (2002) J Biol Chem 277, 47276-84.
- Roberts, H.F. et al. (2005) FEBS Lett 579, 2868-72.
- Doughman, R.L. et al. (2003) J Membr Biol 194, 77-89.
- Wilcox, A. and Hinchliffe, K.A. (2008) FEBS Lett 582, 1391-4.
- Bultsma, Y. et al. (2010) Biochem J 430, 223-35.
- Gozani, O. et al. (2003) Cell 114, 99-111.
- De Matteis, M.A. et al. (2005) Biochim Biophys Acta 1744, 396-405.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.